BACKGROUND & AIMS: Celiac disease (CD) is a common chronic disorder of the small intestine, resulting from aberrant
Introduction
Celiac disease (CD) is a chronic, inflammatory disease of the small intestine induced by dietary proteins in wheat, rye, and barley. It is among the most common genetically determined conditions in humans occurring in 0.5%-1.0% of European populations. 1 Only about one third of the identified patients presents with diarrhea;
another third is diagnosed upon targeted screening, and one fifth presents with nonspecific, recurrent abdominal pain. 2, 3 Evidently, many cases remain undiagnosed and these carry the risk of long-term complications, including growth failure, anemia, osteoporosis, infertility, and cancer. 1, 4 Moreover, they may be at increased risk for a number of CD-associated autoimmune disorders, like type 1 diabetes, dermatitis herpetiformis, autoimmune thyroiditis, and autoimmune hepatitis. 5 CD is a multifactorial disorder. Several genetic factors combined with an environmental trigger are necessary for the disease to develop. Genetic predisposition to CD includes the human leukocyte antigen (HLA)-DQ2 and HLA-DQ8 heterodimers as major risk factors; these are estimated to explain some 40% of the disease heritability. The remaining 60% of the genetic susceptibility to CD is shared between an unknown number of non-HLA genes, each of which is estimated to contribute only a small risk. 6 Recently, the first genome-wide association study on CD and its follow-up have identified 9 non-HLA loci that contribute to CD risk.
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Because CD is a major health problem for both the individual and in the community, a test to identify individuals at high risk would be useful where the diagnosis remains uncertain despite an intestinal biopsy or as part of a long-term screening strategy for asymptomatic indi viduals at familial risk. Our aim is to predict the genetic risk that individuals carry for CD and to assess whether the non-HLA genes can lead to greater risk prediction than HLA alone. This test could be used by clinicians in the prevention, diagnosis, and prognosis of CD.
Methods

Study Populations
Our study included 2 cohorts of CD cases and controls for whom genotype data of HLA and non-HLA risk loci were available. 
Genotyping
The primary HLA association in most CD patients is with DQ2 (more specifically HLA-DQ2.5) and in 5%-10% with DQ8. 12, 13 The risk molecule HLA-DQ2, includes HLA-DQ2.5 (ie, the DQA1*05/DQB1*0201 haplotype) and HLA-DQ2.2 (DQA1*0201/DQB1*0202). We had available genotype data of 3 tag SNPs (rs2395182, rs7775228, and rs2187668) to predict whether an individual had 0, 1, or 2 HLA-DQ2.5 and/or DQ2.2 haplotypes using the tagging SNP approach described by Monsuur et al. 14 DQ8 was not taken into account in this study owing to unavailability of SNP data to predict this haplotype. In addition, from the first genome-wide association study in CD and its follow-up, we included genotype data of 10 SNPs from 9 genomic regions with a genome-wide significant P-value (< 5x10 -7 ; Table 2 ). [7] [8] [9] To assess the non-HLA genotype score, we selected the SNP with the strongest evidence for association at each locus, except for the IL12A/SCHIP locus, for which we included 2 significant but independent SNPs (rs17810546 and rs9811792). 
Data Analysis
We coded genotypes as 0 for the non-risk homozygous genotype, 1 for the heterozygous genotype, and 2
for the homozygous risk genotype. We determined the inheritance model (dominant, recessive, or additive)
for each individual SNP by analyzing the β-coefficients (log [odds ratio (OR)]) of the genotypes as categorical variables in logistic regression models adjusted for gender and population origin (Supplemental Table 1 ). In the dominant model, heterozygous genotypes were recoded as homozygous risk genotypes (weight of 2); in the recessive model, heterozygous genotypes were recoded as homozygous non-risk (0), whereas homozygous risk genotypes were recoded as 1. In the additive model, the risk scores remained unchanged. Hunt et al 7 showed that all SNPs have an independent association with CD, have similar ORs, and show no evidence of interaction between SNPs, so we summed the number of non-HLA risk alleles to obtain a total allele score per individual ( Table 2) .
Several studies have shown that individuals homozygous for HLA-DQ2.5 or HLA-DQ2. Age of onset. Data on age of diagnosis was available for Dutch and UK cases; therefore, we categorized 941 CD patients as early (≤ 12 years; n = 172) or late onset (≥ 18 years; n = 745). Subjects with age of onset between 12 and 18 years (n = 24) were not included in this analysis. Using logistic regression, we estimated the effect of the risk from the total allele score in both groups, adjusting for gender and population group.
Effect of additional risk alleles. Adding risk alleles to the model may increase the accuracy of risk prediction.
Thus, we tested whether including additional SNPs from the same risk locus improved the accuracy of prediction. To estimate the effect of knowing more risk loci, we also performed different simulation models by adding extra simulated loci to the 10 SNPs already selected: (1) adding simulated risk genotypes with similar frequencies and effect sizes; and (2) adding simulated risk genotypes with lower frequencies and effect sizes.
Results
Distribution of HLA and Non-HLA Alleles
We divided the first study population into 3 groups: low risk (4.4% of cases, 53.7% of controls), intermediate risk (49.0% of cases, 40.0% of controls), and high risk (46.6% of cases, 6.4% of controls), based on the dosage effect of the HLA-DQ2 molecule. Figure 1A shows the distribution of the HLA risk groups in cases and controls from the 3 combined populations (Dutch, UK, and Irish). Thus, similar to the literature, around 90% of cases are HLA-DQ2.5 carriers versus 28.1% of controls. [12] [13] [14] 17 Because we know that HLA is necessary but not sufficient for disease development, we created a genetic risk model using the 10 non-HLA SNPs recently identified as independently associated to CD. Both cases and controls display a normal distribution of the total number of risk alleles.
Genetic Risk Model
Logistic regression analysis, adjusted for population, gender, and HLA, shows that an increasing number of risk alleles is associated with an increased risk for CD (Supplemental Figure 1) Figure 3B ).
Effects of Adding Risk Alleles to the Prediction Model
We hypothesized that the risk prediction would improve by adding more risk alleles from the same locus. We therefore included additional SNP data from the IL2/IL21 and LPP loci to the model. However, this did not increase the ORs for these loci.
By using a simulated dataset of risk genotypes with different effect sizes and genotype frequencies, it
was evident that with 10 extra risk genotypes, the OR for the group with the greatest number of risk alleles increased to 12.1. When we included extra genotypes with lower effect sizes and lower frequencies, the OR was 11.6 for the group with the highest number of risk genotypes compared with the reference group (Supplemental Figure 2) .
CHAPTER 5
Using these models, the number of individuals that could be reclassified from intermediate to high risk was approximately 10%, which was similar for each simulation. Thus, it seems that there is a plateau for the number of individuals who can be reclassified, no matter how many new risk loci are identified or what type they are.
Discussion
The recent genome-wide association studies have identified many non-HLA loci for immune-related complex diseases. 20 These loci generally confer only moderate risks with an OR ranging from 1.1 to 1.5, which has
shown by simulation to be sufficient to predict individuals at high risk in the population. 21 In this study, we
show that by combining the individual risk alleles, the risk of developing CD increases, reaching an OR of 6.2 for individuals carrying ≥13 risk alleles. Moreover, using non-HLA risk loci leads to a 7.5% increase (from 31.6% to 33.9%) in the classification of DQ2-positive individuals at high risk for CD compared with taking only their HLA genotype into account. By testing the risk model in an independent population, we have shown that our risk model is valid. Genetic risk prediction should assist in better diagnosis and prognosis strategies; for CD, this would include the early diagnosis of at-risk family members of CD patients who often have unclear symptoms. 4 Identifying newborns at risk for CD by genetic testing would help to target the appropriate group to be followed up more closely by repetition of antibody testing and early biopsy. An early diagnosis means early intervention with a gluten-free diet, which may prevent the development of a more severe disease phenotype or of comorbidities, like other immune-related diseases.
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The first step in classifying CD using genetics should be based on HLA-typing, which identifies 30%-40% of the general population at risk. This group can be further divided into high risk and intermediate risk by combining both HLA and non-HLA risk alleles. With the currently identified non-HLA loci, 33.9% of the HLA-DQ2-positive individuals will fall into the high-risk group (1,142 cases, 328 controls). These non-CD individuals should be followed more closely by serologic screening and, if necessary, by intestinal biopsy because they can be undiagnosed cases in the general population.
Currently, 9 CD risk loci outside HLA have been identified, together accounting for 5% of the explained genetic risk. In future genome-wide association studies, more genes will be identified that will increase the predictive power for genetic tests. However, the question is how many more loci need to be identified to optimize the risk prediction. 7, 8, 11, 20, [23] [24] [25] [26] Moreover, both the shared as well as the disease-specific genes fall into functional categories related to T-cell biology and innate immunity, indicating that these diseases have a shared genetic and functional pathogenesis. Immune-related diseases affect approximately 5%-10% of the general population and often co-occur in patients and in families. 5 We believe that generating a modified risk model to include all the genes shared by immune-related diseases will efficiently identify high-risk individuals, in particular in families with only 1 individual affected by an immune-related disease. We have already made such a risk model in which we included only the genes shared with other immune-related diseases (IL18RAP,
IL2/IL21, RGS1, SH2B3, TAGAP, CCR3, OLIG3-TNFAIP3)
. 7, 8, 11, 20, [23] [24] [25] In this model, the group carrying ≥ 9 risk alleles (3.8% of controls) had a higher risk for CD (OR, 4.8; 95% CI, 3.5-6.5). Soon, we will be able to apply such risk models to other diseases for which prospective cohort studies are available. Because HLA plays a less prominent role in other immune-related diseases than in CD (shown by lower heritability), a risk model based on non-HLA genes may prove to be an even more powerful tool than in CD.
Supplementary Supplemental Figure 2 . Simulation of additional risk alleles to the genetic risk model. 
